Tikun Olam Cannbit Pharmaceuticals Ltd. Logo

Tikun Olam Cannbit Pharmaceuticals Ltd.

A vertically integrated pharma company developing research-backed, EU-GMP medical cannabis products.

TKUN | TA

Overview

Corporate Details

ISIN(s):
IL0010843675
LEI:
Country:
Israel
Address:
Ha'arbaa Street 21, 6473921 Tel Aviv-Yafo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tikun Olam Cannbit Pharmaceuticals Ltd. is a pioneering pharmaceutical company specializing in medical cannabis. The company operates a vertically integrated model, managing the entire value chain from genetics and cultivation to EU-GMP certified manufacturing and distribution. It focuses on developing stable, high-yielding proprietary strains with precise cannabinoid profiles to create standardized, accurately dosed products. A core differentiator is its commitment to research and development, substantiated by over 35 clinical studies and numerous scientific publications that validate the efficacy of cannabis for various medical conditions. The company also provides dedicated clinical nursing support to tens of thousands of patients, guiding their treatment and documenting outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-04-24 14:21
Regulatory News Service
Rights Offering and Identifying Details for New Security: TIKUN OLAM R5
Hebrew (modern) 182.1 KB
2022-08-17 17:30
Regulatory News Service
Opening of Trading On August 18 2022-TIKUN OL CN W3
Hebrew (modern) 107.6 KB
2022-07-26 15:47
Regulatory News Service
Rights Offering and Identifying Details for New Securities-Correction
Hebrew (modern) 185.9 KB
2022-07-26 15:04
Regulatory News Service
Rights Offering and Identifying Details for New Securities-TIKUN OL CAN R4, TIK…
Hebrew (modern) 314.1 KB
2021-05-30 18:08
Regulatory News Service
Tikun Olam-Cannbit – Rights Offering and Identifying Details for New Security
Hebrew (modern) 430.0 KB
2020-10-14 14:50
Regulatory News Service
Tikun Olam Canb – Rights Offering and Identifying Details for New Security
Hebrew (modern) 431.2 KB

Automate Your Workflow. Get a real-time feed of all Tikun Olam Cannbit Pharmaceuticals Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tikun Olam Cannbit Pharmaceuticals Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tikun Olam Cannbit Pharmaceuticals Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.